
Celularity (CELU) Stock Forecast & Price Target
Celularity (CELU) Analyst Ratings
Bulls say
Celularity Inc. is positioned favorably in the biotechnology sector due to its innovative offerings in placental-derived cell therapies, with a current revenue stream predominantly from the bio-banking segment. The company's clinical results, notably the PDA-002, have demonstrated significant ulcer closure rates of 42.8% and 53.8% at 12 and 20 weeks, respectively, which compare positively against established FDA-approved products such as Dermagraft and Dermapace. Furthermore, the enhanced wound healing durability exhibited by PDA-002 underscores the potential for competitive advantage within the regenerative medicine market.
Bears say
Celularity Inc faces significant risks associated with manufacturing failures that could adversely impact its clinical trials, potentially hampering its biobanking and degenerative diseases segments, which are crucial for generating revenue. Furthermore, the declining function of NK cells with age, characterized by reduced cytokine secretion and decreased target cell cytotoxicity, poses a hurdle in effectively utilizing its cell therapy innovations. This combined uncertainty surrounding operational execution and biological efficacy contributes to a negative outlook on the company's stock performance.
This aggregate rating is based on analysts' research of Celularity and is not a guaranteed prediction by Public.com or investment advice.
Celularity (CELU) Analyst Forecast & Price Prediction
Start investing in Celularity (CELU)
Order type
Buy in
Order amount
Est. shares
0 shares